The Mark Foundation for Cancer Research
Drug Discovery Partnership Awards
Last verified:
The Drug Discovery Partnership Awards fund translational research and drug discovery projects to accelerate the conversion of scientific discoveries into cancer therapeutics. The awards support investigators at academic institutions globally, with a focus on projects at TRL 3-6 (from proof-of-concept through early-stage development). This is The Mark Foundation's signature mechanism for bridging bench science and clinical application.
Details
| Funder | The Mark Foundation for Cancer Research |
| TRL | 3-6 |
Eligibility & scope
Accelerates conversion of promising scientific discoveries into cancer therapeutics. Translational/drug discovery focus. Open to investigators at academic institutions globally. No explicit eligibility restrictions stated.
Who Should Apply
- •Researchers at academic institutions globally
- •Projects bridging fundamental discovery and therapeutic development (TRL 3-6)
- •Investigators with strong preliminary data demonstrating translational promise
- •Multidisciplinary teams spanning chemistry, biology, and preclinical validation
Key Dates
- •Check The Mark Foundation website for the current deadline and application cycle
Tips for Applicants
- ✓Emphasise the translational trajectory from your preliminary data to drug candidate; The Mark Foundation prioritises de-risking on the path to IND or equivalent.
- ✓Include clear go/no-go milestones tied to TRL progression; the Foundation values evidence of project management discipline.
- ✓Letters of support from synthetic chemists or pharmaceutical partners strengthen the application if your team lacks deep medicinal chemistry expertise.
Frequently Asked Questions
Who can apply for The Mark Foundation Drug Discovery Partnership Award?
Investigators at academic institutions globally, with projects focused on converting cancer discoveries into therapeutics at TRL 3-6.
What does the Drug Discovery Partnership Award fund?
Translational and drug discovery research aimed at accelerating the conversion of scientific discoveries into cancer therapeutics, from proof-of-concept through early-stage development.
What is the TRL range for Drug Discovery Partnership Award projects?
Projects should sit at TRL 3-6, spanning from proof-of-concept (TRL 3) through early-stage preclinical or clinical development (TRL 6).
Summary generated by AI based on published grant information. Always verify details on the funder's website.
More from The Mark Foundation for Cancer Research
Emerging Leader Award
Deadline: 30 Jul 2026$1,000,000 USD over 4 years ($250,000/year)Aspire Award
Up to $250k (ASPIRE I); up to $500k for clinical studies (ASPIRE I); up to $750k (ASPIRE II); larger amounts for clinical studies (ASPIRE II)Mark Foundation Endeavor Awards
Momentum Fellowships
Postdoctoral Fellowships
Browse Related
Could Drug Discovery Partnership Awards be right for you?
See your personalised match score for this grant and others in 30 seconds. No signup needed to preview.
See my matches free →